SCHEMBL15575210

SCHEMBL15575210

COc1ccc(NC(=O)NCc2ccc(Oc3ccnc(C(=O)O)c3)cc2)cn1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 5/20 0.51
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
PABPC1 P11940 2/20 0.50
CSF1R P07333 1/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
HTT P42858 1/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
P2RX3 P56373 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 1/20 0.45
ROCK2 O75116 1/20 0.44
MAPK14 Q16539 1/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15575227 0.91 MAPK14 (0.55) NAMPTMEN1KMT2ACSF1RCASP3
SCHEMBL16990685 0.85 RAB9A (0.54) NAMPTCSF1RNPC1RAB9AP2RX3
SCHEMBL15574560 0.84 NPC1 (0.58) NAMPTMEN1KMT2ACSF1RHTT
SCHEMBL16990662 0.83 POLB (0.48) NAMPTMEN1KMT2AHTTNPC1
SCHEMBL15574258 0.83 NAMPT (0.59) NAMPTMEN1KMT2ANPC1RAB9A
SCHEMBL16990589 0.83 DDR2 (0.51) NAMPTMEN1KMT2ACSF1RHTT
SCHEMBL15575375 0.82 MAPK14 (0.54) NAMPTMEN1KMT2ACSF1RP2RX3
SCHEMBL16990693 0.82 HDAC1 (0.55) NAMPTMEN1KMT2ANPC1RAB9A
SCHEMBL16990647 0.81 RAB9A (0.52) MEN1KMT2ACSF1RHTTRAB9A
SCHEMBL16990602 0.81 MEN1 (0.50) NAMPTMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 NAMPT 2021/4885MEN1 4251/4885KMT2A 3848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.